Enable Injections
Year founded: 2010
Top executive: Mike Hooven, CEO
Website: enableinjections.com
Describe your company and the product you offer. Enable Injections is an investigational-stage, combination product company with a novel drug delivery technology, enFuse. The enFuse has the potential to allow patients to safely, conveniently and cost-effectively self-administer therapies outside of a clinical facility.
What makes your product innovative? The enFuse on-body infusor is a small wearable device that can deliver large volumes of medicine subcutaneously in a simple administration. It accommodates subcutaneous infusion of up to 50 milliliters of high-viscosity biopharmaceutical and pharmaceutical therapeutics - 20 times more than the potential volume of autoinjectors and substantially larger than the next largest volume of other true wearable infusors in development.
What has been your company’s biggest success to date? Enable Injections has successfully completed two clinical studies with pharmaceutical partners and has formed partnerships with seven pharmaceutical companies.
What’s the next big goal on the horizon? Enable expects to file for combination product regulatory approval with pharmaceutical partners in the coming 12 to 24 months.
